HLA and Adverse Drug Reactions — Risk & Screening — Hands-on

Learn how HLA polymorphisms contribute to severe adverse drug reactions and how pre emptive screening can prevent avoidable toxicity. This module connects immunogenetics, high risk HLA drug pairs and practical laboratory plus reporting workflows for safer, guideline aligned prescribing.

HLA and Adverse Drug Reactions — Risk & Screening

Help Desk · WhatsApp

Session Index

Session 1 — HLA System & Immune ADR Mechanisms Session 2 — High Risk HLA Drug Pairs & Evidence Session 3 — HLA Testing & Screening Workflows Session 4 — Mini Capstone: HLA ADR Risk Report

Session 1

Fee: Rs 8800

HLA System & Immune ADR Mechanisms

HLA genetics and antigen presentation basics

HLA class I vs class II loci and allelic diversity haplotypes and linkage

Immune mediated adverse drug reactions overview

type A vs type B ADRs hypersensitivity syndromes idiosyncratic reactions

Models linking drugs, HLA and T cell activation

hapten and p i concepts altered peptide repertoire organ specific injury patterns

Session 2

Fee: Rs 11800

High Risk HLA Drug Pairs & Evidence

Flagship HLA associated ADR examples

HLA B 57 01 and abacavir HLA B 15 02 and carbamazepine HLA B 58 01 and allopurinol

Phenotypes and clinical pictures to recognize

SJS TEN DRESS drug induced liver injury

Evidence levels and guideline recommendations

strength of association ethnic variation in risk testing recommended vs optional

Session 3

Fee: Rs 14800

HLA Testing & Screening Workflows

Laboratory methods for HLA typing in PGx context

PCR based assays NGS based HLA typing resolution and ambiguity

Pre emptive vs reactive risk screening strategies

before first prescription testing after ADR event panel vs single gene

Clinical workflows and reporting checkpoints

ordering and sample flow turnaround time expectations EMR flags and alerts

Session 4

Fee: Rs 18800

Mini Capstone: HLA ADR Risk Report

Worked case with one high risk HLA drug pair

review clinical scenario connect allele to risk outline screening decision

Structuring an HLA ADR risk and recommendation note

summary statement risk category and actions cautions and limitations

Deliverables: slide deck and one page risk report

PDF or PPTX templated HLA ADR note re usable for clinics

PDF

HLA and Adverse Drug Reactions — Risk & Screening Training | Immunogenetic Risk & PGx Screening Workflows

HLA and Adverse Drug Reactions — Risk & Screening — Hands-on